Harman Patil

Dupilumab

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Type  Whole antibody
Target  IL4 receptor alpha
CAS Number  1190264-60-8
Source  Human
ATC code  none
ChemSpider  none
Dupilumab httpsasthmaallergieschildrencomwpcontentupl

Tsw 1 year successful new dupilumab treatment


Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases. This drug was developed by Regeneron Pharmaceuticals. The US Food and Drug Administration has designated dupilumab a “breakthrough therapy” which is designed to speed promising new drugs to market.

Contents

Dupilumab potentially revolutionize the treatment of atopic dermatitis


Mechanism of action

It binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα). Through blockade of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathway.

Medical uses

The interleukin 4 and 13 pathways have been implicated in the pathophysiology of allergic disease, particularly asthma and atopic dermatitis.

Clinical trials

In 2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating an 87% (placebo: 67%) reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma. In an atopic dermatitis study, 85%(36 percent or 85 out of 671 patients) of patients improved their symptoms by at least 50% within twelve weeks (measured by eczema area and severity index), versus 35% in the placebo group.

In 2016 good results were announced from the SOLO1 and SOLO2 phase III trials (for atopic dermatitis/eczema symptoms) and the US FDA granted it priority review status with a final decision due by March 2017.

References

Dupilumab Wikipedia


Similar Topics
The 10th Kingdom
Ashraf Aman
Len Mitzel
Topics